Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG2501 in Relapsed or Refractory Hematological Malignancies and Lymphoma
NCT05293912Phase 1Terminated
- Sponsor
- Shangjian Bio
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SG2501 in hematological malignancy, lymphoma, multiple myeloma (MM) and 1 more, sponsored by Shangjian Bio. Primary endpoints: Adverse Events and Serious Adverse Events at 24 weeks, Maximum Tolerated Dose at 24 weeks and 1 more. Started Mar 2023; status: terminated.
02
Drugs
SG2501
03
Conditions
hematological malignancylymphomamultiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05293912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293912.